Moving towards individualized medicine with pharmacogenomics

被引：508

作者：

Evans, WE

Relling, MV

机构：

[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[2] Univ Tennessee, Coll Pharm, Chicago, IL USA

[3] Univ Tennessee, Coll Med, Chicago, IL USA

[4] Pharmacogenet Anticanc Agents Res Grp, Chicago, IL USA

[5] Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Memphis, TN 38163 USA

[6] Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA

[7] Pharmacogenet Anticanc Agents Res Grp, Memphis, TN USA

来源：

NATURE | 2004年 / 429卷 / 6990期

关键词：

D O I：

10.1038/nature02626

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Individuals respond differently to drugs and sometimes the effects are unpredictable. Differences in DNA sequences that alter the expression or function of proteins that are targeted by drugs can contribute significantly to variation in the responses of individuals. Many of the genes examined in early studies were linked to highly penetrant, single-gene traits, but future advances hinge on the more difficult challenge of elucidating multi-gene determinants of drug response. This intersection of genomics and medicine has the potential to yield a new set of molecular diagnostic tools that can be used to individualize and optimize drug therapy.

引用

收藏

页码：464 / 468

页数：5

相关论文

共 30 条

[1] With your genes? Take one of these, three times a day [J].

Abbott, A .

NATURE, 2003, 425 (6960) :760-762

[2] Indexing pharmacogenetic knowledge on the World Wide Web [J].

Altman, RB ;

Flockhart, DA ;

Sherry, ST ;

Oliver, DE ;

Rubin, DL ;

Klein, TE .

PHARMACOGENETICS, 2003, 13 (01) :3-5

[3] High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry [J].

Buetow, KH ;

Edmonson, M ;

MacDonald, R ;

Clifford, R ;

Yip, P ;

Kelley, J ;

Little, DP ;

Strausberg, R ;

Koester, H ;

Cantor, CR ;

Braun, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (02) :581-584

[4] The importance of race and ethnic background in biomedical research and clinical practice [J].

Burchard, EG ;

Ziv, E ;

Coyle, N ;

Gomez, SL ;

Tang, H ;

Karter, AJ ;

Mountain, JL ;

Pérez-Stable, EJ ;

Sheppard, D ;

Risch, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (12) :1170-1175

[5] Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells [J].

Cheok, MH ;

Yang, WL ;

Pui, CH ;

Downing, JR ;

Cheng, C ;

Naeve, CW ;

Relling, MV ;

Evans, WE .

NATURE GENETICS, 2003, 34 (01) :85-90

[6] Genetic testing for BRCA1 mutation in the UK [J].

Eccles, DM .

LANCET, 2003, 361 (9352) :178-179

[7]

EICHELBAUM M, 1975, N-S ARCH PHARMACOL, V287, pR94

[8] Gene expression as a drug discovery tool [J].

Evans, WE ;

Guy, RK .

NATURE GENETICS, 2004, 36 (03) :214-215

[9] Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine [J].

Evans, WE ;

Hon, YY ;

Bomgaars, L ;

Coutre, S ;

Holdsworth, M ;

Janco, R ;

Kalwinsky, D ;

Keller, F ;

Khatib, Z ;

Margolin, J ;

Murray, J ;

Quinn, J ;

Ravindranath, Y ;

Ritchey, K ;

Roberts, W ;

Rogers, ZR ;

Schiff, D ;

Steuber, C ;

Tucci, F ;

Kornegay, N ;

Krynetski, EY ;

Relling, MV .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2293-2301

[10] Pharmacogenomics: Translating functional genomics into rational therapeutics [J].

Evans, WE ;

Relling, MV .

SCIENCE, 1999, 286 (5439) :487-491